Liquid sinemet in the management of complex motor fluctuations in advanced Parkinson’s Disease
Objective: To investigate the effectiveness of Levodopa carbidopa ascorbic acid solution (LCAS) in reducing the severity of bradykinesia and dyskinesia in advanced Parkinson’s disease (PD).…Characteristics of dopaminergic treatments in advanced Parkinson’s before levodopa-carbidopa intestinal gel infusion: Data from 107 tested patients
Objective: To describe the characteristics of dopaminergic treatments in a large group of patients with advanced Parkinson’s Disease (APD) in which current non-invasive therapy (oral,…Levodopa-induced dyskinesias in Parkinson disease: A population-based cohort study in Olmsted County, MN (1991-2010)
Objective: To assess the frequency of dyskinesias in a population based-cohort of Parkinson’s disease patients. Background: Levodopa-induced dyskinesias are complications that may impact quality of…Impaired stopping reversed through dopamine replacement in Parkinson’s disease
Objective: Compare the response inhibition of motor process estimated through Stop Signal Reaction Time (SSRT) in Parkinson’s disease (PD) patients and healthy participants and observe…Evaluating long-term effectiveness of carbidopa/levodopa enteral suspension in advanced Parkinson’s Disease patients: PROviDE study design and baseline characteristics
Objective: To evaluate the real-world long-term effectiveness of CLES on advanced PD patients and their caregivers. Background: Carbidopa/levodopa enteral suspension (CLES) was approved in USA…The BeyoND study: Design and baseline characteristics of a study evaluating the long-term safety of ND0612 for motor fluctuations in Parkinson’s disease
Objective: Describe the design and baseline characteristics of a long-term (1 year) study of 2 ND0612 dose regimens, with emphasis on systemic and local safety…The highly selective 5-HT2A receptor antagonist EMD-281,014 alleviates L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To investigate the effect of the highly-selective serotonin 2A (5-HT2A ) receptor antagonist EMD-281,014 at alleviating L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesia in the 6-hydroxydopamine (6-OHDA)-lesioned rat.…Huntington disease like 2 in South Africa
Objective: Background: Since the Huntingtin gene was identified in 1993, it has been recognized that a small proportion of patients with a clinical syndrome resembling…L-Dopa Responsiveness is Correlated to Fluorodeoxyglucose Metabolism and Dopamine Transporter Availability in Parkinson’s Disease
Objective: We aim to explore if the degree of l-dopa responsiveness would be correlated to metabolism level in specific brain areas by using 18F-FDG and…Final Safety Results of EASE LID 2 Study: Long Term Open-Label Study of ADS-5102 for Dyskinesia in Parkinson’s disease (PD) patients
Objective: The primary objective of this study was the safety and tolerability of ADS-5102 in PD patients with dyskinesia. Secondary efficacy outcome measures included MDS-UPDRS,…
- « Previous Page
- 1
- …
- 45
- 46
- 47
- 48
- 49
- …
- 62
- Next Page »